Press release content from Business Wire. The AP news staff was not involved in its creation.
UKONIQ™ (umbralisib) Now Approved by the FDA; Onco360® Selected as Exclusive Specialty Pharmacy Partner
February 8, 2021 GMT
LOUISVILLE, Ky. (BUSINESS WIRE) Feb 8, 2021
Onco360 ®, the nation’s largest independent Oncology Pharmacy, has been selected by TG Therapeutics, Inc. to be the exclusive specialty pharmacy partner for UKONIQ TM (umbralisib), a new oral treatment for adult patients with relapsed refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed refractory follicular lymphoma who have received at least three prior lines of systemic therapy. These indications are approved under accelerated approval based on overall response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Infinite Ore Reports up to 1.60% Li2O From Shallow Surface Drilling at Jackpot Lithium Project
February 8, 2021 GMT
VANCOUVER, BC / ACCESSWIRE / February 8, 2021 / Infinite Ore Corp. (the Company ) (TSXV:ILI)(OTCQB:ARXRF) is pleased to announce drill results from a previous drill program completed on its 100% owned Jackpot Lithium Project in Ontario. While .
VANCOUVER, BC / ACCESSWIRE / February 8, 2021 / Infinite Ore Corp. (the Company ) (TSXV:ILI)(OTCQB:ARXRF) is pleased to announce drill results from a previous drill program completed on its 100% owned Jackpot Lithium Project in Ontario. While .
Press release content from Business Wire. The AP news staff was not involved in its creation.
ICON Launches FIRECREST Safety Letters and Site Question Management Supporting Regulatory Compliance and Increasing Site Support
February 8, 2021 GMT
DUBLIN (BUSINESS WIRE) Feb 8, 2021
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of two new digital solutions supporting clinical research sites and sponsors. The FIRECREST suite of digital clinical solutions are now integrated with the ICON Safety Reporting solution to enable electronic acknowledgement of safety letters by principal investigators, with full compliance tracking and dashboard reporting. The FIRECREST Site Question Management solution automates, accelerates and tracks medical questions from the site for quicker resolution.